Physicians should be aware that PLP can occur after initiation of paclitaxel.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[40]]}, "Treatment": {"text": [["paclitaxel"]], "start": [[66]], "Drug": {"text": [["paclitaxel"]], "start": [[66]]}}, "Effect": {"text": [["PLP"]], "start": [[32]]}, "Speculated": {"text": [["can"]], "start": [[36]], "value": true}}]}]
Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[60]]}, "Effect": {"text": [["thrombocytopenia"]], "start": [[68]]}, "Treatment": {"text": [["heparin"]], "start": [[52]], "Drug": {"text": [["heparin"]], "start": [[52]]}}}]}]
Treatment of lithium tremor with metoprolol.
[{"events": [{"event_type": "Potential_therapeutic_event", "Trigger": {"text": [["Treatment of"]], "start": [[0]]}, "Treatment": {"text": [["metoprolol"]], "start": [[33]], "Disorder": {"text": [["lithium tremor"]], "start": [[13]]}, "Drug": {"text": [["lithium"], ["metoprolol"]], "start": [[13], [33]]}}}]}]
A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[44]]}, "Subject": {"text": [["A 54-year-old man"]], "start": [[0]], "Age": {"text": [["54-year-old"]], "start": [[2]]}, "Gender": {"text": [["man"]], "start": [[14]]}}, "Treatment": {"text": [["amiodarone"]], "start": [[32]], "Drug": {"text": [["amiodarone"]], "start": [[32]]}}, "Effect": {"text": [["thyrotoxicosis"]], "start": [[54]]}}]}]
Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["adverse drug reaction"]], "start": [[35]]}, "Treatment": {"text": [["isoniazid therapy"]], "start": [[64]], "Drug": {"text": [["isoniazid"]], "start": [[64]]}}, "Effect": {"text": [["Gynaecomastia"]], "start": [[0]]}}]}]
The authors performed a literature search using PubMed and the search terms "gemcitabine" and "radiation recall" to find prior cases of radiation recall attributed to gemcitabine.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["attributed"]], "start": [[153]]}, "Treatment": {"text": [["gemcitabine"]], "start": [[167]], "Drug": {"text": [["gemcitabine"]], "start": [[167]]}}, "Subject": {"text": [["prior cases"]], "start": [[121]]}, "Effect": {"text": [["radiation recall"]], "start": [[136]]}}]}]
Carbamazepine-induced Diabetes mellitus.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]]}, "Effect": {"text": [["Diabetes mellitus"]], "start": [[22]]}, "Treatment": {"text": [["Carbamazepine"]], "start": [[0]], "Drug": {"text": [["Carbamazepine"]], "start": [[0]]}}}]}]
She displayed symptoms of ST 8 days after the introduction of linezolid.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["displayed"]], "start": [[4]]}, "Treatment": {"text": [["8 days after the introduction of linezolid"]], "start": [[29]], "Time_elapsed": {"text": [["8 days"]], "start": [[29]]}, "Route": {"text": [["introduction"]], "start": [[46]]}, "Drug": {"text": [["linezolid"]], "start": [[62]]}}, "Effect": {"text": [["symptoms of ST"]], "start": [[14]]}, "Subject": {"text": [["She"]], "start": [[0]], "Gender": {"text": [["She"]], "start": [[0]]}}}]}]
Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["include"]], "start": [[91]]}, "Treatment": {"text": [["Naproxen"]], "start": [[0]], "Drug": {"text": [["Naproxen"]], "start": [[0]]}}, "Effect": {"text": [["tinnitus and transient hearing loss"]], "start": [[99]]}}]}]
The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["adverse"]], "start": [[52]]}, "Effect": {"text": [["hypersensitivity syndrome"]], "start": [[16]]}, "Treatment": {"text": [["allopurinol"]], "start": [[4]], "Drug": {"text": [["allopurinol"]], "start": [[4]]}}}]}]
The pulmonary toxicity is probably induced by piritrexim.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[35]]}, "Effect": {"text": [["pulmonary toxicity"]], "start": [[4]]}, "Treatment": {"text": [["piritrexim"]], "start": [[46]], "Drug": {"text": [["piritrexim"]], "start": [[46]]}}, "Speculated": {"text": [["probably"]], "start": [[26]], "value": true}}]}]
BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[29]]}, "Treatment": {"text": [["Interferon (IFN)"]], "start": [[12]], "Drug": {"text": [["Interferon"]], "start": [[12]]}}, "Effect": {"text": [["retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus"]], "start": [[40]]}}]}]
We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["complicated"]], "start": [[139]]}, "Subject": {"text": [["a patient with a liver abscess due to Entamoeba histolytica"]], "start": [[12]]}, "Treatment": {"text": [["metronidazole therapy (total dose, 21 g over 14 days)"]], "start": [[81]], "Drug": {"text": [["metronidazole"]], "start": [[81]]}, "Dosage": {"text": [["21 g"]], "start": [[116]]}, "Duration": {"text": [["14 days"]], "start": [[126]]}, "Disorder": {"text": [["liver abscess"], ["Entamoeba histolytica"]], "start": [[29], [50]]}}, "Effect": {"text": [["reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess"]], "start": [[154]]}}]}]
We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.
[{"events": [{"event_type": "Potential_therapeutic_event", "Trigger": {"text": [["received"]], "start": [[94]]}, "Subject": {"text": [["a Japanese male patient who underwent a living-donor kidney transplantation", "immunosuppression"]], "start": [[11, 159]], "Race": {"text": [["Japanese"]], "start": [[13]]}, "Gender": {"text": [["male"]], "start": [[22]]}, "Disorder": {"text": [["kidney transplantation"]], "start": [[64]]}}, "Treatment": {"text": [["tacrolimus, mycophenolate mofetil, and prednisolone"]], "start": [[103]], "Disorder": {"text": [["immunosuppression"]], "start": [[159]]}, "Drug": {"text": [["tacrolimus"], ["mycophenolate mofeti"], ["prednisolone"]], "start": [[103], [115], [142]]}, "Combination": [{"event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[138]]}, "Drug": {"text": [["tacrolimus"], ["mycophenolate mofeti"], ["prednisolone"]], "start": [[103], [115], [142]]}}]}}]}]
Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[17]]}, "Effect": {"text": [["Gold nephropathy"]], "start": [[0]]}, "Treatment": {"text": [["auranofin"]], "start": [[24]], "Drug": {"text": [["Gold"], ["auranofin"], ["tolmetin"]], "start": [[0], [24], [46]]}}}]}]
We report three cases of amiodarone-induced torsades de pointe.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[36]]}, "Subject": {"text": [["three cases"]], "start": [[10]], "Population": {"text": [["three"]], "start": [[10]]}}, "Treatment": {"text": [["amiodarone"]], "start": [[25]], "Drug": {"text": [["amiodarone"]], "start": [[25]]}}, "Effect": {"text": [["torsades de pointe"]], "start": [[44]]}}]}]
Torsades de pointes due to drug interaction between disopyramide and clarithromycin.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[20]]}, "Treatment": {"text": [["drug interaction between disopyramide and clarithromycin"]], "start": [[27]], "Drug": {"text": [["disopyramide"], ["clarithromycin"]], "start": [[52], [69]]}, "Combination": [{"event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[32]]}, "Drug": {"text": [["disopyramide"], ["clarithromycin"]], "start": [[52], [69]]}}]}, "Effect": {"text": [["Torsades de pointes"]], "start": [[0]]}}]}]
We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[26]]}, "Subject": {"text": [["a patient"]], "start": [[12]]}, "Effect": {"text": [["HUS"]], "start": [[36]]}, "Treatment": {"text": [["mitomycin C (total dose 144 mg/m2)"]], "start": [[61]], "Drug": {"text": [["mitomycin C"]], "start": [[61]]}, "Dosage": {"text": [["144 mg/m2"]], "start": [[85]]}, "Disorder": {"text": [["carcinoma of the ascending colon"]], "start": [[105]]}}}]}]
In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["interact"]], "start": [[341]]}, "Treatment": {"text": [["5-FU increased PHT, which in turn may have increased the PB concentration"]], "start": [[14]], "Drug": {"text": [["5-FU"], ["PHT"]], "start": [[14], [29]]}, "Combination": [{"event_type": "Combination", "Trigger": {"text": [["increased", "PB"]], "start": [[19, 71]]}, "Drug": {"text": [["5-FU"], ["PHT"]], "start": [[14], [29]]}}]}, "Effect": {"text": [["secondary effects of antitumor agents on other drugs"]], "start": [[270]]}, "Subject": {"text": [["patients"]], "start": [[164]]}, "Speculated": {"text": [["suggesting"]], "start": [[89]], "value": true}}]}]
Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[48]]}, "Effect": {"text": [["Severe loss of vision"]], "start": [[0]]}, "Treatment": {"text": [["intravitreal triamcinolone", "photodynamic"]], "start": [[58, 105]], "Drug": {"text": [["triamcinolone"], ["photodynamic"]], "start": [[71], [105]]}, "Disorder": {"text": [["exudative age-related macular degeneration"]], "start": [[130]]}, "Combination": [{"event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[88]]}, "Drug": {"text": [["triamcinolone"], ["photodynamic"]], "start": [[71], [105]]}}]}}]}]
The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.
[{"events": [{"event_type": "Potential_therapeutic_event", "Trigger": {"text": [["enhances"]], "start": [[45]]}, "Subject": {"text": [["patients with advanced NSCLC"]], "start": [[83]]}, "Treatment": {"text": [["tirapazamine"]], "start": [[32]], "Drug": {"text": [["tirapazamine"]], "start": [[32]]}, "Disorder": {"text": [["advanced NSCLC"]], "start": [[97]]}}, "Effect": {"text": [["enhances the activity of cisplatin"]], "start": [[45]]}}]}]
Cardiac arrest associated with sulprostone use during caesarean section.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[15]]}, "Effect": {"text": [["Cardiac arrest"]], "start": [[0]]}, "Treatment": {"text": [["sulprostone"]], "start": [[31]], "Drug": {"text": [["sulprostone"]], "start": [[31]]}}}]}]
Linear IgA bullous dermatosis occurring after carbamazepine.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[30]]}, "Effect": {"text": [["Linear IgA bullous dermatosis"]], "start": [[0]]}, "Treatment": {"text": [["carbamazepine"]], "start": [[46]], "Drug": {"text": [["carbamazepine"]], "start": [[46]]}}}]}]
Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.
[{"events": [{"event_type": "Potential_therapeutic_event", "Trigger": {"text": [["beneficial"]], "start": [[18]]}, "Treatment": {"text": [["Erythropoietin"]], "start": [[0]], "Disorder": {"text": [["mitomycin-induced hemolytic-uremic syndrome"]], "start": [[32]]}, "Drug": {"text": [["Erythropoietin"]], "start": [[0]]}}}, {"event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[42]]}, "Treatment": {"text": [["mitomycin"]], "start": [[32]], "Drug": {"text": [["mitomycin"]], "start": [[32]]}}, "Effect": {"text": [["hemolytic-uremic syndrome"]], "start": [[50]]}}]}]
Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[16]]}, "Effect": {"text": [["Hypothyroidism"]], "start": [[0]]}, "Subject": {"text": [["11 percent of patients"]], "start": [[35]], "Population": {"text": [["11 percent"]], "start": [[35]]}}, "Treatment": {"text": [["amiodarone"]], "start": [[71]], "Drug": {"text": [["amiodarone"]], "start": [[71]]}}, "Speculated": {"text": [["potential"]], "start": [[176]], "value": true}}]}]
We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[47]]}, "Effect": {"text": [["herpes esophagitis"]], "start": [[28]]}, "Subject": {"text": [["a renal transplant patient"]], "start": [[50]]}, "Treatment": {"text": [["Cyclosporine A while on chronic steroid therapy"]], "start": [[90]], "Drug": {"text": [["Cyclosporine A"], ["chronic steroid"]], "start": [[90], [114]]}, "Disorder": {"text": [["renal transplant"]], "start": [[52]]}, "Combination": [{"event_type": "Combination", "Trigger": {"text": [["while"]], "start": [[105]]}, "Drug": {"text": [["Cyclosporine A"], ["chronic steroid"]], "start": [[90], [114]]}}]}}]}]
Severe hepatocellular dysfunction following cyproterone acetate therapy.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[34]]}, "Effect": {"text": [["Severe hepatocellular dysfunction"]], "start": [[0]]}, "Treatment": {"text": [["cyproterone acetate"]], "start": [[44]], "Drug": {"text": [["cyproterone acetate"]], "start": [[44]]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "value": "High"}}]}]
It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["immunoallergic reaction"]], "start": [[176]]}, "Effect": {"text": [["3-week sulphasalazine syndrome"]], "start": [[118]]}, "Treatment": {"text": [["sulphasalazine"]], "start": [[203]], "Drug": {"text": [["sulphasalazine"]], "start": [[203]]}}, "Severity": {"text": [["fatal"]], "start": [[169]], "value": "High"}}]}]
Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[87]]}, "Subject": {"text": [["Two patients with bipolar affective disorder and a history of bronchospastic phenomena"]], "start": [[0]], "Population": {"text": [["Two"]], "start": [[0]]}, "Disorder": {"text": [["a history of bronchospastic phenomena"]], "start": [[49]]}}, "Effect": {"text": [["tremor"]], "start": [[99]]}, "Treatment": {"text": [["lithium carbonate therapy"]], "start": [[113]], "Drug": {"text": [["lithium carbonate"]], "start": [[113]]}, "Disorder": {"text": [["bipolar affective disorder"]], "start": [[18]]}}}]}]
Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["nephrotoxic effect"]], "start": [[53]]}, "Effect": {"text": [["Acute renal failure"]], "start": [[0]]}, "Treatment": {"text": [["captopril"]], "start": [[75]], "Drug": {"text": [["captopril"]], "start": [[75]]}}, "Subject": {"text": [["chronically hypoperfused kidneys"]], "start": [[88]], "Disorder": {"text": [["chronically hypoperfused kidneys"]], "start": [[88]]}}, "Speculated": {"text": [["most likely"]], "start": [[20]], "value": true}}]}]
We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[65]]}, "Treatment": {"text": [["radiotherapy-enhanced aminoglutethimide"]], "start": [[20]], "Disorder": {"text": [["metastatic breast cancer"]], "start": [[92]]}, "Drug": {"text": [["aminoglutethimide"]], "start": [[42]]}}, "Effect": {"text": [["skin toxicity"]], "start": [[60]]}, "Subject": {"text": [["a patient with metastatic breast cancer"]], "start": [[77]]}}]}]
Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[101]]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[54]]}, "Treatment": {"text": [["serotonergic drugs"]], "start": [[108]], "Drug": {"text": [["serotonergic drugs"]], "start": [[108]]}}, "Subject": {"text": [["a patient"]], "start": [[91]]}, "Speculated": {"text": [["possibility"]], "start": [[39]], "value": true}}]}]
Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[54]]}, "Treatment": {"text": [["methyldopa"]], "start": [[43]], "Drug": {"text": [["methyldopa"]], "start": [[43]]}}, "Effect": {"text": [["liver injury"]], "start": [[62]]}, "Speculated": {"text": [["may"]], "start": [[103]], "value": true}}]}]
In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[74]]}, "Subject": {"text": [["eight patients"]], "start": [[3]], "Population": {"text": [["eight"]], "start": [[3]]}}, "Effect": {"text": [["mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L"]], "start": [[21]]}, "Treatment": {"text": [["a single 200 mg intravenous dose of lorcainide"]], "start": [[89]], "Dosage": {"text": [["a single 200 mg"]], "start": [[89]]}, "Route": {"text": [["intravenous"]], "start": [[105]]}, "Drug": {"text": [["lorcainide"]], "start": [[125]]}}}]}]
Nitrendipine-induced gingival hyperplasia.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]]}, "Treatment": {"text": [["Nitrendipine"]], "start": [[0]], "Drug": {"text": [["Nitrendipine"]], "start": [[0]]}}, "Effect": {"text": [["gingival hyperplasia"]], "start": [[21]]}}]}]
Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[119]]}, "Subject": {"text": [["a patient with definite seronegative rheumatoid arthritis"]], "start": [[57]]}, "Effect": {"text": [["hypogammaglobulinemia"]], "start": [[129]]}, "Treatment": {"text": [["gold therapy"]], "start": [[168]], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[94]]}, "Drug": {"text": [["gold"]], "start": [[168]]}}}]}]
When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[102]]}, "Subject": {"text": [["he"]], "start": [[99]]}, "Effect": {"text": [["weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."]], "start": [[112]]}, "Treatment": {"text": [["SASP was changed to 5-aminosalicylic acid (5-ASA)"]], "start": [[5]], "Drug": {"text": [["SASP"], ["5-aminosalicylic acid"]], "start": [[5], [25]]}}}, {"event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[80]]}, "Treatment": {"text": [["SASP was changed to 5-aminosalicylic acid (5-ASA)"]], "start": [[5]], "Disorder": {"text": [["skin eruptions"]], "start": [[60]]}, "Drug": {"text": [["5-aminosalicylic acid"], ["SASP"]], "start": [[25], [5]]}}}]}]
One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[23]]}, "Treatment": {"text": [["tacrolimus", "after lung transplantation (LT)"]], "start": [[12, 54]], "Drug": {"text": [["tacrolimus"]], "start": [[12]]}}, "Effect": {"text": [["hepatic VOD"]], "start": [[31]]}}]}]
We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[64]]}, "Subject": {"text": [["an NHL patient"]], "start": [[22]]}, "Treatment": {"text": [["rituximab"]], "start": [[50]], "Disorder": {"text": [["NHL"]], "start": [[25]]}, "Drug": {"text": [["rituximab"]], "start": [[50]]}}, "Effect": {"text": [["symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP)"]], "start": [[74]]}}]}]
We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[78]]}, "Subject": {"text": [["76-year-old woman"]], "start": [[60]], "Age": {"text": [["76-year-old"]], "start": [[60]]}, "Gender": {"text": [["woman"]], "start": [[72]]}}, "Treatment": {"text": [["long-term disopyramide", "clarithromycin"]], "start": [[85, 128]], "Disorder": {"text": [["chronic bronchitis"]], "start": [[161]]}, "Drug": {"text": [["long-term disopyramide"], ["clarithromycin"]], "start": [[85], [128]]}, "Combination": [{"event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[43]]}, "Drug": {"text": [["long-term disopyramide"], ["clarithromycin"]], "start": [[85], [128]]}}]}, "Effect": {"text": [["TdP"]], "start": [[22]]}}]}]
Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[139]]}, "Treatment": {"text": [["infliximab"]], "start": [[144]], "Drug": {"text": [["infliximab"]], "start": [[144]]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[91]]}}, "Effect": {"text": [["sleep disordered breathing"]], "start": [[30]]}, "Subject": {"text": [["rheumatoid arthritis patients"]], "start": [[91]]}}]}]
We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[69]]}, "Treatment": {"text": [["adenosine infusion"]], "start": [[79]], "Drug": {"text": [["adenosine"]], "start": [[79]]}, "Route": {"text": [["infusion"]], "start": [[89]]}}, "Effect": {"text": [["sustained monomorphic ventricular tachycardia"]], "start": [[23]]}}]}]
Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["Provocation"]], "start": [[0]]}, "Subject": {"text": [["three adolescent patients"]], "start": [[65]], "Population": {"text": [["three"]], "start": [[65]]}, "Age": {"text": [["adolescent"]], "start": [[71]]}}, "Treatment": {"text": [["tiagabine"]], "start": [[52]], "Drug": {"text": [["tiagabine"]], "start": [[52]]}}, "Effect": {"text": [["non-convulsive status epilepticus"]], "start": [[15]]}}]}]
We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[91]]}, "Treatment": {"text": [["quinine"]], "start": [[83]], "Drug": {"text": [["quinine"]], "start": [[83]]}}, "Effect": {"text": [["quinine-associated thrombotic microangiopathy (quinine-TMA)"]], "start": [[83]]}}]}]
The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[59]]}, "Treatment": {"text": [["discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects"]], "start": [[74]], "Drug": {"text": [["antidepressant"], ["amoxapine"]], "start": [[108], [93]]}}, "Effect": {"text": [["oral-facial dyskinesia"]], "start": [[31]]}}]}]
A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.
[{"events": [{"event_type": "Potential_therapeutic_event", "Trigger": {"text": [["initiated"]], "start": [[48]]}, "Subject": {"text": [["A 34-year-old HIV-infected man"]], "start": [[0]], "Disorder": {"text": [["disseminated Histoplasma capsulatum infection"]], "start": [[116]]}, "Age": {"text": [["34-year-old"]], "start": [[2]]}, "Gender": {"text": [["man"]], "start": [[27]]}}, "Treatment": {"text": [["initiated efavirenz-based antiretroviral therapy"]], "start": [[48]], "Disorder": {"text": [["HIV"]], "start": [[14]]}, "Drug": {"text": [["efavirenz"], ["antiretroviral"]], "start": [[58], [74]]}, "Combination": [{"event_type": "Combination", "Trigger": {"text": [["based"]], "start": [[68]]}, "Drug": {"text": [["efavirenz"], ["antiretroviral"]], "start": [[58], [74]]}}]}}]}]
Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.
[{"events": [{"event_type": "Potential_therapeutic_event", "Trigger": {"text": [["and"]], "start": [[69]]}, "Treatment": {"text": [["Aminoglutethimide was discontinued until completion of radiotherapy"]], "start": [[0]], "Drug": {"text": [["Aminoglutethimide"]], "start": [[0]]}}, "Effect": {"text": [["the rash resolved"]], "start": [[73]]}}]}]
We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["explored"]], "start": [[3]]}, "Effect": {"text": [["ophthalmic and neurologic findings"]], "start": [[12]]}, "Subject": {"text": [["two children"]], "start": [[50]], "Population": {"text": [["two"]], "start": [[50]]}, "Age": {"text": [["children"]], "start": [[54]]}}, "Treatment": {"text": [["exposed prenatally to VGB"], ["VGB"]], "start": [[77], [99]]}}]}]
Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[96]]}, "Treatment": {"text": [["heavy betel nut consumption", "depot neuroleptics"]], "start": [[159, 72]], "Disorder": {"text": [["chronic schizophrenic"]], "start": [[27]]}, "Drug": {"text": [["depot neuroleptics"], ["betel nut"]], "start": [[72], [165]]}}, "Subject": {"text": [["Two cases"]], "start": [[0]], "Population": {"text": [["Two"]], "start": [[0]]}}, "Effect": {"text": [["severe extrapyramidal symptoms"]], "start": [[106]]}}]}]
Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.
[{"events": [{"event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[79]]}, "Subject": {"text": [["younger individuals"]], "start": [[59]], "Age": {"text": [["younger"]], "start": [[59]]}}, "Treatment": {"text": [["intake of clioquinol"]], "start": [[85]], "Drug": {"text": [["clioquinol"]], "start": [[95]]}, "Route": {"text": [["intake"]], "start": [[85]]}}, "Effect": {"text": [["acute amnestic episode"]], "start": [[33]]}}]}]
